全文获取类型
收费全文 | 2734篇 |
免费 | 135篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 49篇 |
儿科学 | 58篇 |
妇产科学 | 13篇 |
基础医学 | 528篇 |
口腔科学 | 91篇 |
临床医学 | 214篇 |
内科学 | 654篇 |
皮肤病学 | 51篇 |
神经病学 | 249篇 |
特种医学 | 68篇 |
外科学 | 369篇 |
综合类 | 8篇 |
预防医学 | 82篇 |
眼科学 | 45篇 |
药学 | 200篇 |
中国医学 | 12篇 |
肿瘤学 | 197篇 |
出版年
2023年 | 15篇 |
2022年 | 26篇 |
2021年 | 36篇 |
2020年 | 25篇 |
2019年 | 43篇 |
2018年 | 32篇 |
2017年 | 52篇 |
2016年 | 34篇 |
2015年 | 37篇 |
2014年 | 51篇 |
2013年 | 74篇 |
2012年 | 130篇 |
2011年 | 148篇 |
2010年 | 86篇 |
2009年 | 78篇 |
2008年 | 122篇 |
2007年 | 132篇 |
2006年 | 133篇 |
2005年 | 157篇 |
2004年 | 110篇 |
2003年 | 134篇 |
2002年 | 109篇 |
2001年 | 136篇 |
2000年 | 82篇 |
1999年 | 98篇 |
1998年 | 31篇 |
1997年 | 20篇 |
1996年 | 23篇 |
1995年 | 19篇 |
1994年 | 23篇 |
1993年 | 27篇 |
1992年 | 83篇 |
1991年 | 54篇 |
1990年 | 49篇 |
1989年 | 60篇 |
1988年 | 47篇 |
1987年 | 42篇 |
1986年 | 44篇 |
1985年 | 30篇 |
1984年 | 28篇 |
1983年 | 25篇 |
1982年 | 13篇 |
1981年 | 13篇 |
1979年 | 16篇 |
1978年 | 14篇 |
1977年 | 20篇 |
1970年 | 11篇 |
1969年 | 16篇 |
1967年 | 14篇 |
1966年 | 14篇 |
排序方式: 共有2888条查询结果,搜索用时 15 毫秒
61.
Nogawa T Takahashi S Okano A Kawatani M Uramoto M Saito T Osada H 《The Journal of antibiotics》2012,65(3):123-128
Two new 6,6-spiroacetal polyketides, spirotoamides A (1) and B (2), were isolated from a microbial metabolite fraction library of Streptomyces griseochromogenes JC82-1223 by screening of structurally unique compounds based on a search of spectral database. The fraction library was constructed using a systematic separation method to efficiently discover new metabolites from microbial sources such as actinomycetes and fungi. The structures of 1 and 2 were elucidated by 2D-NMR and mass spectrometric measurements. They belong to a class of polyketides, and contain a 6,6-spiroacetal core structure and a carboxamide group. The biosynthetic pathway of 1 and 2 is discussed in the text. 相似文献
62.
63.
64.
Sakti Chakrabarti Jaskanwal Sara Ronstan Lobo Rachel Eiring Heidi Finnes Jessica Mitchell Mindy Hartgers Akiko Okano Thorvardur Halfdanarson Axel Grothey 《Clinical colorectal cancer》2019,18(1):52-57
Introduction
Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU. Given the additional benefit of oxaliplatin over FP alone in the management of colorectal cancer, retaining oxaliplatin in the treatment regimen is desirable, but the safety of combining bolus 5-FU with oxaliplatin in patients with FP-induced vasospasm is not well established. We performed a retrospective review to explore the safety of substituting FLOX (bolus 5-FU, oxaliplatin, leucovorin) for FOLFOX (infusional 5-FU, oxaliplatin, leucovorin) and CAPOX (capecitabine, oxaliplatin) in patients who had FP-induced coronary vasospasm.Patients and Methods
The pharmacy database of Mayo Clinic was queried to identify patients who developed coronary vasospasm associated with FOLFOX or CAPOX between January 2011 and January 2018 and were subsequently treated with FLOX. Detailed information was obtained on these patients by retrospective electronic chart review.Results
A total of 10 patients (median age, 56.5 years; range, 36-77 years) were identified, 9 with FOLFOX and 1 with CAPOX. Among the patients treated with FOLFOX, 8 patients had chest pain as the presenting complaint that had started within 48 hours of beginning of the 5-FU infusion. In 9 of 10 patients, coronary vasospasm occurred with the first cycle of therapy. All patients made full recovery after discontinuation of infusional 5-FU or capecitabine. All patients subsequently received FLOX with 7 median bolus 5-FU doses (range, 2-22 doses) and 7 median oxaliplatin doses (range, 2-12 doses) at 7 days to 18 months after the event, with 7 patients treated within 4 weeks of the event. FLOX did not cause any cardiovascular adverse events in any of the 10 patients.Conclusion
Bolus 5-FU in combination with oxaliplatin is safe in patients who have experienced coronary vasospasm with infusional 5-FU or capecitabine. 相似文献65.
66.
Kuriyama M Kato J Kuwaki K Morimoto N Nawa T Fujimoto T Kono H Okano N Miyaike J Morita T Okada H Suzuki S Yoshioka T Shiode J Suwaki K Sakaguchi K Shiratori Y;Japan West Ulcerative Colitis Study Group 《European journal of gastroenterology & hepatology》2008,20(7):634-641
BACKGROUND AND AIM: The health-related quality of life (HRQOL) of patients with ulcerative colitis (UC) can be impaired because of the chronic symptoms. Although UC patients suffer from such symptoms over the long term, there have been few reports on the changes of HRQOL with disease duration. The aim of this study was to clarify these changes. METHODS: The HRQOL of 331 Japanese UC patients was examined using the validated Japanese version of the Inflammatory Bowel Disease Questionnaire (J-IBDQ). HRQOL and factors affecting HRQOL identified using multiple linear regression analysis were stratified by disease duration. RESULTS: Of the 15 clinical factors examined, the clinical activity index score was the strongest determinant (P<0.0001) of all the scores of IBDQ regardless of disease duration. HRQOL did not differ significantly among patients with different disease durations. The factors, however, that affected HRQOL varied according to disease duration. In patients with disease duration of less than 5 years, the clinical activity index score was the predominant factor affecting HRQOL. Being 'on sick leave or hospitalized' was a significant factor impairing HRQOL in patients with disease duration of 5-9 years. Moreover, complications due to corticosteroids significantly impaired all of the IBDQ scores in patients with disease duration of 10 years or more. CONCLUSION: Factors that affected the HRQOL of UC patients varied according to the patients' disease duration. Our findings should assist in the development of a long-term strategy for the treatment of UC patients. 相似文献
67.
Nobuya Kobayashi Hideki Kobara Noriko Nishiyama Masao Fujiwara Keiichi Okano 《Minimally invasive therapy & allied technologies》2018,27(4):203-208
Background: Endoscopic submucosal dissection (ESD) techniques, such as generating an artificial space between digestive tract layers for safer dissection, were thought to be safer for the resection of organs in cholecystectomy. We investigated whether combinations of endoscopic techniques and laparoscopic techniques could be performed more safely and rapidly.Material and methods: Laparoscopic and endoscopic cooperative-cholecystectomy (LEC-chole) and conventional laparoscopic cholecystectomy (Lapa-chole) were performed in six dogs. Operation time was defined as the time from the creation of the first port to the retrieval of the resected gallbladder (GB); and GB bed dissection time was the time from local injection of natural saline to the clipping of the cystic duct. The main roles of the endoscope in LEC-chole were to obtain a sufficient cutting space via local injection of natural saline to the GB bed and to monitor the operative view without laparoscopic camera, thus omitting the umbilical port.Results: The operation times were 60?±?18.3?minutes for LEC-chole and 95?±?7.0 for Lapa-chole (p?=?.036). The GB bed dissection times were 31?±?8.54?minutes in LEC-chole and 50.6?±?7.37?minutes in Lapa-chole (p?=?0.048). There were significant differences in liver damage and bleeding (p?=?0.116), but there were no significant differences in one-month survival.Conclusions: The application of LEC-chole may be expanded to cholecystectomy. 相似文献
68.
C V Oddis Y Okano W A Rudert M Trucco R J Duquesnoy T A Medsger 《Arthritis and rheumatism》1992,35(10):1211-1217
OBJECTIVE. The inflammatory myopathies are characterized by distinctive autoantibodies that are associated with certain clinical features and immunogenetic patterns. Anti-PM-Scl is one such antibody and is found in pure myositis, myositis in overlap, and systemic sclerosis (SSc). Our purpose was to describe the clinical and immunogenetic associations of the anti-PM-Scl antibody. METHODS. Serum samples from 617 patients with various connective tissue diseases were screened for anti-PM-Scl antibody by indirect immunofluorescence and Ouchterlony double immunodiffusion. Patients with anti-PM-Scl were serologically typed for HLA-DR and DQ, and the genes encoding DQ alpha and DQ beta were characterized by hybridization of sequence-specific oligonucleotide to amplified genomic DNA. RESULTS. Twenty-three patients (4%) had serum anti-PM-Scl. Sixteen had either pure myositis or myositis in overlap, 6 had SSc alone, and 1 had SSc and rheumatoid arthritis. Twenty of the antibody-positive patients had serologic HLA typing performed; 15 (75%) were HLA-DR3 positive, and 17 (85%) expressed the DQw2 allele. None of the 5 DR3 negative patients shared a unique DR or DQ antigen with the DR3 positive patients, and further DNA analysis of 10 patients (4 of whom were DR3 negative) did not reveal any unique DQ alleles. CONCLUSION. Anti-PM-Scl identifies a subset of patients with myositis, SSc, or an overlap of the two disorders, and this antibody has a strong but not exclusive immunogenetic association with the HLA-DR3 antigen. 相似文献
69.
70.
Ken Komatsu Masayoshi Hashimoto Yukari Okano Takuya Keima Yugo Kitazawa Takamichi Nijo Shuichiro Takahashi Kensaku Maejima Yasuyuki Yamaji Shigetou Namba 《Archives of virology》2013,158(7):1579-1582
Radish mosaic virus (RaMV) is a crucifer-infecting comovirus that has been detected worldwide. Here, we report the successful construction of a full-length infectious cDNA clone of RaMV. The full-length cDNA clones corresponding to RNA1 and RNA2 of a Japanese isolate of RaMV were cloned into the pBlueScript plasmid or the binary vector pCAMBIA1301 downstream of the cauliflower mosaic virus 35S promoter. Mechanical inoculation or agroinoculation of Nicotiana benthamiana with these vectors resulted in systemic RaMV infections causing symptoms similar to those caused by the wild-type parental virus. The presence of progeny virus was verified by western blot analysis and electron microscopy. 相似文献